Causes of screen failures (February 2011 through April 2017), N = 561
Cause . | n/N . | % . |
---|---|---|
Failed eligibility criteria | 233/561 | 41 |
Multiple comorbidity | 135/233 | |
Thrombocytopenia | 32/233 | |
Neutropenia | 3/233 | |
Pancytopenia | 15/233 | |
Relapsed or graft failure | 29/233 | |
Secondary malignancy | 5/233 | |
Other | 14/233 | |
Patient was not interested | 129/561 | 23 |
Physician was not interested (some received AZA off-study) | 84/561 | 15 |
Detectable minimal residual disease after transplant (received AZA off-study) | 26/561 | 5 |
No clinical trial benefit | 28/561 | 5 |
Outside physician refused | 10/561 | 2 |
On competing IND study | 10/561 | 2 |
Cause . | n/N . | % . |
---|---|---|
Failed eligibility criteria | 233/561 | 41 |
Multiple comorbidity | 135/233 | |
Thrombocytopenia | 32/233 | |
Neutropenia | 3/233 | |
Pancytopenia | 15/233 | |
Relapsed or graft failure | 29/233 | |
Secondary malignancy | 5/233 | |
Other | 14/233 | |
Patient was not interested | 129/561 | 23 |
Physician was not interested (some received AZA off-study) | 84/561 | 15 |
Detectable minimal residual disease after transplant (received AZA off-study) | 26/561 | 5 |
No clinical trial benefit | 28/561 | 5 |
Outside physician refused | 10/561 | 2 |
On competing IND study | 10/561 | 2 |
AZA, azacitidine; IND, investigational new drug.